Kolb SJ, Kissel JT (2011) Spinal muscular atrophy: a timely review. Arch Neurol 68:979–984. https://doi.org/10.1001/archneurol.2011.74

Article  PubMed  PubMed Central  Google Scholar 

Verhaart IEC, Robertson A, Wilson IJ et al (2017) Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis 12:1–15. https://doi.org/10.1186/s13023-017-0671-8

Article  Google Scholar 

Nash LA, Burns JK, Chardon JW et al (2016) Spinal muscular atrophy: more than a disease of motor neurons? Curr Mol Med 16:779–792. https://doi.org/10.2174/1566524016666161128113338

Article  CAS  PubMed  Google Scholar 

Abati E, Citterio G, Bresolin N et al (2020) Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease? Neurobiol Dis 140:104870. https://doi.org/10.1016/j.nbd.2020.104870

Article  CAS  PubMed  Google Scholar 

Bürglen L, Lefebvre S, Clermont O et al (1996) Structure and organization of the human survival motor neurone (SMN) gene. Genomics 32:479–482. https://doi.org/10.1006/geno.1996.0147

Article  PubMed  Google Scholar 

Messina S, Sframeli M (2020) New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. https://doi.org/10.3390/jcm9072222

Article  PubMed  PubMed Central  Google Scholar 

Farrar MA, Kiernan MC (2015) The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 12:290–302. https://doi.org/10.1007/s13311-014-0314-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walter MC, Wenninger S, Thiele S et al (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study. J Neuromuscul Dis 6:453–465. https://doi.org/10.3233/JND-190416

Article  PubMed  PubMed Central  Google Scholar 

Deutsch L, Osredkar D, Plavec J, Stres B (2021) Spinal muscular atrophy after Nusinersen therapy: improved physiology in pediatric patients with no significant change in urine, serum, and liquor 1H-NMR metabolomes in comparison to an age-matched, healthy cohort. Metabolites. https://doi.org/10.3390/metabo11040206

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-z

Article  PubMed  Google Scholar 

Hayden JA, van der Windt DA, Cartwright JL et al (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158:280–286. https://doi.org/10.7326/0003-4819-158-4-201302190-00009

Article  PubMed  Google Scholar 

Beaudin M, Kamali T, Tang W et al (2023) Cerebrospinal fluid proteomic changes after Nusinersen in patients with spinal muscular atrophy. J Clin Med. https://doi.org/10.3390/jcm12206696

Article  PubMed  PubMed Central  Google Scholar 

Bianchi L, Sframeli M, Vantaggiato L et al (2021) Nusinersen modulates proteomics profiles of cerebrospinal fluid in spinal muscular atrophy type 1 patients. Int J Mol Sci. https://doi.org/10.3390/ijms22094329

Article  PubMed  PubMed Central  Google Scholar 

Musso G, Bello L, Capece G et al (2024) Neurofilament light chain and profilin-1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen. Eur J Neurol. https://doi.org/10.1111/ene.16393

Article  PubMed  PubMed Central  Google Scholar 

Olsson B, Alberg L, Cullen NC et al (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266:2129–2136. https://doi.org/10.1007/s00415-019-09389-8

Article  PubMed  PubMed Central  Google Scholar 

Orbach R, Sagi L, Sadot E et al (2022) Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy. Muscle Nerve 66:762–766. https://doi.org/10.1002/mus.27731

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panicucci C, Sahin E, Bartolucci M et al (2024) Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy. Cell Mol Life Sci. https://doi.org/10.1007/s00018-024-05426-6

Article  PubMed  PubMed Central  Google Scholar 

Paris A, Bora P, Parolo S et al (2023) A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen. CPT: Pharmacometrics & Systems Pharmacology 12:196–206. https://doi.org/10.1002/psp4.12890

Article  CAS  Google Scholar 

Scheijmans FEV, Cuppen I, Zwartkruis MM et al (2023) Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment. Eur J Paediatr Neurol 42:34–41. https://doi.org/10.1016/j.ejpn.2022.12.003

Article  CAS  PubMed  Google Scholar 

Schorling DC, Kölbel H, Hentschel A et al (2022) Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol 29:2084–2096. https://doi.org/10.1111/ene.15331

Article  PubMed  Google Scholar 

Totzeck A, Stolte B, Kizina K et al (2019) Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci. https://doi.org/10.3390/ijms20215397

Article  PubMed  PubMed Central  Google Scholar 

Verma S, Perry K, Razdan R et al (2023) CSF IL-8 associated with response to gene therapy in a case series of spinal muscular atrophy. Neurotherapeutics 20:245–253. https://doi.org/10.1007/s13311-022-01305-9

Article  CAS  PubMed  Google Scholar 

De Wel B, De Schaepdryver M, Poesen K, Claeys KG (2022) Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months. Ann Clin Transl Neurol 9:1241–1251. https://doi.org/10.1002/acn3.51625

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonanno S, Cavalcante P, Salvi E et al (2022) Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment. Front Cell Neurosci 16:1–15. https://doi.org/10.3389/fncel.2022.982760

Article  CAS  Google Scholar 

Zandl-Lang M, Züllig T, Holzer M et al (2025) Multi-omics profiling in spinal muscular atrophy (SMA): investigating lipid and metabolic alterations through longitudinal CSF analysis of Nusinersen-treated patients. J Neurol 272:183. https://doi.org/10.1007/s00415-025-12909-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brkušanin M, Kosać A, Branković-Srećković V et al (2024) Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia. Front Neurol 15:1–11. https://doi.org/10.3389/fneur.2024.1394001

Article  Google Scholar 

Chen L, Liu F, Fang D, Li J (2023) Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children. Front Pediatr 11:1–8. https://doi.org/10.3389/fped.2023.1294405

Article  Google Scholar 

Faravelli I, Gagliardi D, Abati E et al (2023) Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study. Cell Mol Life Sci 80:1–18. https://doi.org/10.1007/s00018-023-04885-7

Article  CAS  Googl